Peter Dines has been appointed as an Investment Director, Head of Life Sciences, at technology investment specialist Mercia Fund Management. He joins three other heads of sector and investment directors at Mercia. He has two decades’ experience of the healthcare sector, having founded and run a number of healthcare technology businesses.
Career highlights have included turning around obstetrics equipment firm Surgicraft, which was subsequently sold to ISIS Equity Partners, and founding spinal and orthopaedic medical technology business Surgi C Group, and distribution platform Newtech Ortho, both of which were subsequently acquired by private equity.
Dines holds several directorships across a range of life sciences businesses, including pharmaceuticals firm Cisiv, ultrasound service provider Diagnostic World and Spring Active.
Managing Director of Mercia Fund Management Mark Payton said: “Peter brings significant experience and specialist expertise to the growing team at Mercia. He is highly regarded for his track record in identifying opportunities and growing value rapidly through hands-on management in businesses in the medtech and life sciences sector.
“He joins the three other sector-specific investment directors who lead our investment activity in digital; electronics and hardware; and advanced materials, engineering and specialised manufacturing.
“His remit across the life sciences sector will focus specifically on medtech, contract services and diagnostics.”
Dines said: “I am delighted to be joining Mercia at this exciting time of expansion for the company. I believe the offering of Mercia fund structures combined with expert support to assist growth is a very attractive proposition to early-stage technology companies. I am very much looking forward to using my past experience to help create new high-growth businesses in the life sciences and healthcare sector.”